{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["89(5)"],"submitter":["Romano LGR"],"pubmed_abstract":["<h4>Aims</h4>Nadroparin is administered to COVID-19 intensive care unit (ICU) patients as thromboprophylaxis. Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID-19 ICU patients is unknown. Moreover, optimal dosing regimens achieving anti-Xa target levels (0.3-0.7 IU/mL) are unknown. Therefore, a population PK analysis was conducted to investigate different dosing regimens of nadroparin in COVID-19 ICU patients.<h4>Methods</h4>Anti-Xa levels (n = 280) from COVID-19 ICU patients (n = 65) receiving twice daily (BID) 5700 IU of subcutaneous nadroparin were collected to perform a population PK analysis with NONMEM v7.4.1. Using Monte Carlo simulations (n = 1000), predefined dosing regimens were evaluated.<h4>Results</h4"],"journal":["British journal of clinical pharmacology"],"pagination":["1617-1628"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9878197"],"repository":["biostudies-literature"],"pubmed_title":["Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients."],"pmcid":["PMC9878197"],"pubmed_authors":["Endeman H","Romano LGR","Hunfeld NGM","Kruip MJHA","Preijers T"],"additional_accession":[]},"is_claimable":false,"name":"Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID-19 intensive care unit patients.","description":"<h4>Aims</h4>Nadroparin is administered to COVID-19 intensive care unit (ICU) patients as thromboprophylaxis. Despite existing population pharmacokinetic (PK) models for nadroparin in literature, the population PK of nadroparin in COVID-19 ICU patients is unknown. Moreover, optimal dosing regimens achieving anti-Xa target levels (0.3-0.7 IU/mL) are unknown. Therefore, a population PK analysis was conducted to investigate different dosing regimens of nadroparin in COVID-19 ICU patients.<h4>Methods</h4>Anti-Xa levels (n = 280) from COVID-19 ICU patients (n = 65) receiving twice daily (BID) 5700 IU of subcutaneous nadroparin were collected to perform a population PK analysis with NONMEM v7.4.1. Using Monte Carlo simulations (n = 1000), predefined dosing regimens were evaluated.<h4>Results</h4","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-04-18T14:06:06.694Z","creation":"2025-04-06T23:59:56.451Z"},"accession":"S-EPMC9878197","cross_references":{"pubmed":["36495312"],"doi":["10.1111/bcp.15634"]}}